CoChat

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease

Open access
Boza-Serrano, Antonio, Vrillon, Agathe, Minta, Karolina, Paulus, Agnes, Camprubí-Ferrer, Lluís, Garcia, Megg, Andreasson, Ulf, Antonell, Anna, Wennström, Malin, Gouras, Gunnar, Dumurgier, Julien, Cognat, Emmanuel, Molina-Porcel, Laura, Balasa, Mircea, Vitorica, Javier, Sánchez-Valle, Raquel, Paquet, Claire, Venero, Jose Luis, Blennow, Kaj, Deierborg, Tomas · 2022 · Acta Neuropathologica

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Galectin-3 (Gal-3) is a beta-galactosidase binding protein involved in microglial activation in the central nervous system (CNS). We previously demonstrated the crucial deleterious role of Gal-3 in microglial activation in Alzheimer’s disease (AD). Under AD conditions, Gal-3 is primarily expressed by microglial cells clustered around Aβ plaques in both human and mouse brain, and knocking out Gal-3 reduces AD pathology in AD-model mice. To further unravel the importance of Gal-3-associated inflammation in AD, we aimed to investigate the Gal-3 inflammatory response in the AD continuum. First, we measured Gal-3 levels in neocortical and hippocampal tissue from early-onset AD patients, including genetic and sporadic cases. We found that Gal-3 levels were significantly higher in both cortex and hippocampus in AD subjects. Immunohistochemistry revealed that Gal-3+ microglial cells were associated with amyloid plaques of a larger size and more irregular shape and with neurons containing tau-inclusions. We then analyzed the levels of Gal-3 in cerebrospinal fluid (CSF) from AD patients ( n = 119) compared to control individuals ( n = 36). CSF Gal-3 levels were elevated in AD patients compared to controls and more strongly correlated with tau (p-Tau181 and t-tau) and synaptic markers (GAP-43 and neurogranin) than with amyloid-β. Lastly, principal component analysis (PCA) of AD biomarkers revealed that CSF Gal-3 clustered and associated with other CSF neuroinflammatory markers, including sTREM-2, GFAP, and YKL-40. This neuroinflammatory component was more highly expressed in the CSF from amyloid-β positive (A+), CSF p-Tau181 positive (T+), and biomarker neurodegeneration positive/negative (N+/−) (A + T + N+/−) groups compared to the A + T−N− group. Overall, Gal-3 stands out as a key pathological biomarker of AD pathology that is measurable in CSF and, therefore, a potential target for disease-modifying therapies involving the neuroinflammatory response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-022-02469-6

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Gal-3 levels are increased in the cortex and the hippocampus in AD patients. First, Gal-3 levels were compared between AD samples versus control samples (a). Gal-3 levels measured by ELISA are increased in cortical and hippocampal tissue from AD patients compared to controls (b). c AD patients were divided into sporadic early-onset AD (EOAD) and genetic AD (PSEN1 mutation) cases. Then, Gal-3 levels were compared between AD groups and controls. d, e Cortical and hippocampal Gal-3 levels were compared between EOAD and genetic AD groups. Differences were found compared to control samples but not between EOAD and genetic AD groups themselves. Non-parametric t-test a and Kruskal–Wallis multiple comparisons (b-e) were performed. Data are shown as mean ± SEM. **p < 0.01; ***p < 0.001. ****p < 0.0001
Fig. 1 Gal-3 levels are increased in the cortex and the hippocampus in AD patients. First, Gal-3 levels were compared between AD samples versus control samples (a). Gal-3 levels measured by ELISA are increased in cortical and hippocampal tissue from AD patients compared to controls (b). c AD patients were divided into sporadic early-onset AD (EOAD) and genetic AD (PSEN1 mutation) cases. Then, Gal-3 levels were compared between AD groups and controls. d, e Cortical and hippocampal Gal-3 levels were compared between EOAD and genetic AD groups. Differences were found compared to control samples but not between EOAD and genetic AD groups themselves. Non-parametric t-test a and Kruskal–Wallis multiple comparisons (b-e) were performed. Data are shown as mean ± SEM. **p < 0.01; ***p < 0.001. ****p < 0.0001CC BY · PubMed Central
Fig. 2 Gal-3-positive microglial cells are associated with larger and more irregularly shaped Aβ plaques. a Gal-3-positive microglial cells were associated with larger and more irregularly shaped Aβ plaques (Gal3+ plaques) compared to Gal-3-negative Aβ plaques (Gal3− plaques). b, c Gal3+ plaques were larger and more irregularly shaped than Gal-3− plaques. Aβ (red), Galectin-3 (green), Iba1 (white). Data are shown as mean ± SEM. Non-parametric t-tests were performed. ****p < 0.0001. (n = 3 (HC), n = 8 (AD). Gal-3-negative plaques, n = 212; Gal-3-positive plaques, n = 197)
Fig. 2 Gal-3-positive microglial cells are associated with larger and more irregularly shaped Aβ plaques. a Gal-3-positive microglial cells were associated with larger and more irregularly shaped Aβ plaques (Gal3+ plaques) compared to Gal-3-negative Aβ plaques (Gal3− plaques). b, c Gal3+ plaques were larger and more irregularly shaped than Gal-3− plaques. Aβ (red), Galectin-3 (green), Iba1 (white). Data are shown as mean ± SEM. Non-parametric t-tests were performed. ****p < 0.0001. (n = 3 (HC), n = 8 (AD). Gal-3-negative plaques, n = 212; Gal-3-positive plaques, n = 197)CC BY · PubMed Central
Fig. 3 Reactive microglial cells expressing Gal-3 presented Aβ inclusions in human tissue samples. a–f Gal-3-positive microglial cell associated with Aβ plaques. g 3D reconstruction of microglial cells with multiple Aβ inclusions inside. Gal3 (green), Aβ (red), Iba1 (white), DAPI (blue). White arrows are pointing to Aβ inclusions (in red) (n = 3 (HC), n = 8 (AD)
Fig. 3 Reactive microglial cells expressing Gal-3 presented Aβ inclusions in human tissue samples. a–f Gal-3-positive microglial cell associated with Aβ plaques. g 3D reconstruction of microglial cells with multiple Aβ inclusions inside. Gal3 (green), Aβ (red), Iba1 (white), DAPI (blue). White arrows are pointing to Aβ inclusions (in red) (n = 3 (HC), n = 8 (AD)CC BY · PubMed Central
Fig. 4 Reactive microglial cells expressing Gal-3 interact with p-Tau in senile plaques from human tissue samples. a–f Gal-3-positive microglial cell associated with p-Tau plaques. g 3D reconstruction of microglial cell with multiple p-Tau interactions. Gal3 (green), p-Tau (red), Iba1 (white) and DAPI (blue). White arrows are pointing p-Tau Gal-3 interactions (in orange). n = 3 (HC), n = 8 (AD)
Fig. 4 Reactive microglial cells expressing Gal-3 interact with p-Tau in senile plaques from human tissue samples. a–f Gal-3-positive microglial cell associated with p-Tau plaques. g 3D reconstruction of microglial cell with multiple p-Tau interactions. Gal3 (green), p-Tau (red), Iba1 (white) and DAPI (blue). White arrows are pointing p-Tau Gal-3 interactions (in orange). n = 3 (HC), n = 8 (AD)CC BY · PubMed Central
Fig. 5 CSF Gal-3 levels are increased in AD patients and correlate with other CSF neuroinflammatory biomarkers. a CSF Gal-3 levels were measured by ELISA in control subjects and AD patients. Gal-3 levels were significantly elevated in AD patients compared to controls (*P = 0.030) after adjustment on age, sex and ApoE4 carriership. b CSF sTREM-2 levels were measured in our cohort. No difference was found between the AD and control groups in our analysis adjusted for age, sex and ApoE4 carriership (P = 0.217). c, d Analysis of ROC curves revealed moderate performance of CSF Gal-3 and sTREM-2 levels for differentiating AD patients from neurological controls (c Gal-3 AUROC = 0.80 [95% CI = 0.72–0.88], sTREM-2 AUROC = 0.78 [95% CI = 0.69–0.88]; d Gal-3 AUPRC = 0.92, sTREM-2 AUPRC = 0.91). For comparison, CSF markers p-tau and t-tau demonstrated high discriminating performance between AD and controls (c: p-tau AUROC = 0.95 [95% CI = 0.91–1.00], t-tau AUROC = 0.92 [95% CI = 0.86–0.98]; 5d: p-tau AUPRC = 1.00, t-tau AUPRC = 0.99). e, f, g The relationships between CSF Gal-3 and other CSF neuroinflammatory biomarkers—sTREM-2, GFAP and YKL-40—were studied using Spearman’s rank correlation in the whole cohort as well as in AD and neurological control (NC) subgroups
Fig. 5 CSF Gal-3 levels are increased in AD patients and correlate with other CSF neuroinflammatory biomarkers. a CSF Gal-3 levels were measured by ELISA in control subjects and AD patients. Gal-3 levels were significantly elevated in AD patients compared to controls (*P = 0.030) after adjustment on age, sex and ApoE4 carriership. b CSF sTREM-2 levels were measured in our cohort. No difference was found between the AD and control groups in our analysis adjusted for age, sex and ApoE4 carriership (P = 0.217). c, d Analysis of ROC curves revealed moderate performance of CSF Gal-3 and sTREM-2 levels for differentiating AD patients from neurological controls (c Gal-3 AUROC = 0.80 [95% CI = 0.72–0.88], sTREM-2 AUROC = 0.78 [95% CI = 0.69–0.88]; d Gal-3 AUPRC = 0.92, sTREM-2 AUPRC = 0.91). For comparison, CSF markers p-tau and t-tau demonstrated high discriminating performance between AD and controls (c: p-tau AUROC = 0.95 [95% CI = 0.91–1.00], t-tau AUROC = 0.92 [95% CI = 0.86–0.98]; 5d: p-tau AUPRC = 1.00, t-tau AUPRC = 0.99). e, f, g The relationships between CSF Gal-3 and other CSF neuroinflammatory biomarkers—sTREM-2, GFAP and YKL-40—were studied using Spearman’s rank correlation in the whole cohort as well as in AD and neurological control (NC) subgroupsCC BY · PubMed Central
Fig. 6 CSF Gal-3 levels correlate with CSF tau and synaptic markers. a–o Scatter plots depicting the association between CSF Gal-3 levels with other CSF AD and synaptic markers in the whole cohort and in the sub-groups (neurological controls [NC] n = 36 and AD n = 119). a–c CSF Aβ ratio weakly correlated with CSF Gal-3 in the whole cohort and sub-groups. d–i CSF Gal-3 significantly correlated with CSF p-tau181 and t-tau in the whole cohort and some sub-groups. j–o CSF Gal-3 levels correlated with CSF synaptic markers neurogranin j–l and GAP-43 m–o in the whole cohort and in the AD patient sub-group. Associations were assessed using Spearman’s rank correlation. Solid line indicates regression line, and dotted lines border the 95% confidence interval
Fig. 6 CSF Gal-3 levels correlate with CSF tau and synaptic markers. a–o Scatter plots depicting the association between CSF Gal-3 levels with other CSF AD and synaptic markers in the whole cohort and in the sub-groups (neurological controls [NC] n = 36 and AD n = 119). a–c CSF Aβ ratio weakly correlated with CSF Gal-3 in the whole cohort and sub-groups. d–i CSF Gal-3 significantly correlated with CSF p-tau181 and t-tau in the whole cohort and some sub-groups. j–o CSF Gal-3 levels correlated with CSF synaptic markers neurogranin j–l and GAP-43 m–o in the whole cohort and in the AD patient sub-group. Associations were assessed using Spearman’s rank correlation. Solid line indicates regression line, and dotted lines border the 95% confidence intervalCC BY · PubMed Central
Fig. 7 CSF Gal-3 clusters with a neuroinflammatory component in principal component analysis. a, b Principal component analysis (PCA) in the whole cohort revealed clustering of the CSF biomarkers in two principal components (a loading values of each CSF biomarker, eigenvalues, and variance explained for each component identified; b: scree-plot in Varimax rotation). Component 1 is associated with CSF core AD biomarkers (Aß ratio, p-Tau181, and t-tau) and CSF synaptic markers (neurogranin, GAP-43). Component 2 included the CSF neuroinflammation markers (Gal-3, sTREM-2, GFAP, and YKL-40). Component 1 and Component 2 accounted for 57% and 14% of the variance. c–e Identified components were compared between groups using one-way ANCOVA-adjusted on age and sex followed by post hoc Least square test, adjusted with Bonferroni for multiple comparisons. c Core AD Component 1 was significantly higher in AD patients than in all other groups (****P < 0.0001 versus all other groups). d Neuroinflammation Component 2 did not differ between the groups. e Focusing on the patients on the AD continuum, neuroinflammatory Component 2 was significantly higher in patients with a [A + T + N +] CSF profile compared to patients with an [A + T−N−] profile (P = 0.002)
Fig. 7 CSF Gal-3 clusters with a neuroinflammatory component in principal component analysis. a, b Principal component analysis (PCA) in the whole cohort revealed clustering of the CSF biomarkers in two principal components (a loading values of each CSF biomarker, eigenvalues, and variance explained for each component identified; b: scree-plot in Varimax rotation). Component 1 is associated with CSF core AD biomarkers (Aß ratio, p-Tau181, and t-tau) and CSF synaptic markers (neurogranin, GAP-43). Component 2 included the CSF neuroinflammation markers (Gal-3, sTREM-2, GFAP, and YKL-40). Component 1 and Component 2 accounted for 57% and 14% of the variance. c–e Identified components were compared between groups using one-way ANCOVA-adjusted on age and sex followed by post hoc Least square test, adjusted with Bonferroni for multiple comparisons. c Core AD Component 1 was significantly higher in AD patients than in all other groups (****P < 0.0001 versus all other groups). d Neuroinflammation Component 2 did not differ between the groups. e Focusing on the patients on the AD continuum, neuroinflammatory Component 2 was significantly higher in patients with a [A + T + N +] CSF profile compared to patients with an [A + T−N−] profile (P = 0.002)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 66

Metadata

Authors
Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., Dumurgier, J., Cognat, E., Molina-Porcel, L., Balasa, M., Vitorica, J., Sánchez-Valle, R., Paquet, C., Venero, J. L., Blennow, K., & Deierborg, T.
Affiliations
  • Inserm (FR)
  • University of Gothenburg (SE)
  • Lund University (SE)
  • Hospital Clínic de Barcelona (ES)
  • Instituto de Biomedicina de Sevilla (ES)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Vrillon, Agathe
Venue
Acta Neuropathologica
Published
2022-07-27
Volume
144
Issue
5
Pages
843-859
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W4288177782
Cited by
66
References
63
Citations by year
2026: 15 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 3
FWCI
7.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Vetenskapsrådet (2019-0633)
  • Ministerio de Ciencia, Innovación y Universidades (RTI2018-098645-B-100, PID2021-124096OB-100)
  • Instituto de Salud Carlos III (20/00448, Union PI18/01556, PI21/00914)
  • Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (P18-RT-1372, US-1262734)
  • Kungliga Fysiografiska Sällskapet i Lund (20191114ABS, 20211129ABS)
  • Greta och Johan Kocks stiftelser (20201201ABS)
  • Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (US-1264806)
  • Lund University
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
galectin-3, Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid plaques, tau inclusions, neuroinflammation, microglial activation, p-tau181, neurogranin, GAP-43, glial fibrillary acidic protein, YKL-40, hippocampus, neocortex, early-onset Alzheimer's disease, disease-modifying therapy
MeSH terms
Chitinase-3-Like Protein 1, Alzheimer Disease, Animals, beta-Galactosidase, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, GAP-43 Protein, Galectin 3, Mice, Neurogranin, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s00401-022-02469-6
The paper
Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., Dumurgier, J., Cognat, E., Molina-Porcel, L., Balasa, M., Vitorica, J., Sánchez-Valle, R., Paquet, C., Venero, J. L., Blennow, K., & Deierborg, T. (2022). Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-022-02469-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.